These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 1646112)

  • 1. Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules.
    Tamura S; Funato H; Hirabayashi Y; Suzuki Y; Nagamine T; Aizawa C; Kurata T
    Eur J Immunol; 1991 Jun; 21(6):1337-44. PubMed ID: 1646112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine.
    Tamura SI; Asanuma H; Ito Y; Hirabayashi Y; Suzuki Y; Nagamine T; Aizawa C; Kurata T; Oya A
    Eur J Immunol; 1992 Feb; 22(2):477-81. PubMed ID: 1537382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit.
    Tamura S; Ito Y; Asanuma H; Hirabayashi Y; Suzuki Y; Nagamine T; Aizawa C; Kurata T
    J Immunol; 1992 Aug; 149(3):981-8. PubMed ID: 1634780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
    Hasegawa H; Ichinohe T; Strong P; Watanabe I; Ito S; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T
    J Med Virol; 2005 Jan; 75(1):130-6. PubMed ID: 15543590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza.
    Tamura S; Funato H; Hirabayashi Y; Kikuta K; Suzuki Y; Nagamine T; Aizawa C; Nakagawa M; Kurata T
    Vaccine; 1990 Oct; 8(5):479-85. PubMed ID: 2251874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
    Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
    Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.
    Ichinohe T; Watanabe I; Ito S; Fujii H; Moriyama M; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T; Hasegawa H
    J Virol; 2005 Mar; 79(5):2910-9. PubMed ID: 15709010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
    Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus.
    Asahi-Ozaki Y; Yoshikawa T; Iwakura Y; Suzuki Y; Tamura S; Kurata T; Sata T
    J Med Virol; 2004 Oct; 74(2):328-35. PubMed ID: 15332283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity.
    Liew FY; Russell SM; Appleyard G; Brand CM; Beale J
    Eur J Immunol; 1984 Apr; 14(4):350-6. PubMed ID: 6609824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the usefulness of intranasal inactivated influenza vaccines.
    Tamura S
    Vaccine; 2010 Aug; 28(38):6393-7. PubMed ID: 20493820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines.
    Asahi Y; Yoshikawa T; Watanabe I; Iwasaki T; Hasegawa H; Sato Y; Shimada S; Nanno M; Matsuoka Y; Ohwaki M; Iwakura Y; Suzuki Y; Aizawa C; Sata T; Kurata T; Tamura S
    J Immunol; 2002 Mar; 168(6):2930-8. PubMed ID: 11884464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.
    Sandbulte MR; Jimenez GS; Boon AC; Smith LR; Treanor JJ; Webby RJ
    PLoS Med; 2007 Feb; 4(2):e59. PubMed ID: 17298168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation.
    Chen J; Fang F; Li X; Chang H; Chen Z
    Vaccine; 2005 Jul; 23(34):4322-8. PubMed ID: 15925433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TH cells primed during influenza virus infection provide help for qualitatively distinct antibody responses to subsequent immunization.
    Marshall D; Sealy R; Sangster M; Coleclough C
    J Immunol; 1999 Nov; 163(9):4673-82. PubMed ID: 10528164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defense mechanisms against influenza virus infection in the respiratory tract mucosa.
    Tamura S; Kurata T
    Jpn J Infect Dis; 2004 Dec; 57(6):236-47. PubMed ID: 15623947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice.
    Prabakaran M; Madhan S; Prabhu N; Geng GY; New R; Kwang J
    Antiviral Res; 2010 May; 86(2):180-7. PubMed ID: 20153776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A protective immune response in mice to viral components other than hemagglutinin in a live influenza A virus vaccine model.
    Horimoto T; Takada A; Iwatsuki-Horimoto K; Kawaoka Y
    Vaccine; 2004 Jun; 22(17-18):2244-7. PubMed ID: 15149783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.